Gene therapy for neurodegenerative disorders
Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.
1. A method of modulating motor function in a subject with spinal muscular atrophy (SMA) comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a recombinant adeno-associated virus (rAAV) virion to the central nervous system of the subject; wherein the rAAV virion comprises a self-complementary adeno-associated virus (scAAV) vector comprising a polynucleotide encoding a survival motor neuron (SMN) protein, wherein the rAAV virion comprises an AAV9 capsid, wherein the composition is administered via administration into at least one region of the deep cerebellar nuclei of the cerebellum, via direct spinal cord injection, via intracerebroventricular injection, or via intrathecal injection.
2. The method of claim 1 , wherein the composition is administered via intracerebroventricular injection into at least one cerebral lateral ventricle.
3. The method of claim 1 , wherein the composition is administered via both intracerebroventricular injection and direct spinal cord injection.
4. The method of claim 1 , wherein the SMN protein is encoded by human SMN-1.
5. The method of claim 4 , wherein the SMN protein comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO:2.
6. The method of claim 5 , wherein the SMN protein comprises an amino acid sequence of SEQ ID NO:2.
7. The method of claim 1 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.